Related Experiment Video
Updated: Jun 23, 2025
Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
No Effect of Methylnaltrexone on Acute Pancreatitis Severity: A Multicenter Randomized Controlled Trial
Cecilie Siggaard Knoph1,2, Mathias Ellgaard Cook1,2, Srdan Novovic3,4
1Mech-Sense and Centre for Pancreatic Diseases, Department of Gastroenterology & Hepatology, Aalborg University Hospital, Aalborg, Denmark.
Introduction:
Opioids used to manage severe pain in acute pancreatitis (AP) might exacerbate the disease through effects on gastrointestinal and immune functions. Methylnaltrexone, a peripherally acting µ-opioid receptor antagonist, may counteract these effects without changing analgesia.
Methods:
This double-blind, randomized, placebo-controlled trial included adult patients with AP and systemic inflammatory response syndrome at 4 Danish centers. Patients were randomized to receive 5 days of continuous intravenous methylnaltrexone (0.15 mg/kg/d) or placebo added to the standard of care. The primary end point was the Pancreatitis Activity Scoring System score after 48 hours of treatment. Main secondary outcomes included pain scores, opioid use, disease severity, and mortality.
Results:
In total, 105 patients (54% men) were randomized to methylnaltrexone (n = 51) or placebo (n = 54). After 48 hours, the Pancreatitis Activity Scoring System score was 134.3 points in the methylnaltrexone group and 130.5 points in the placebo group (difference 3.8, 95% confidence interval [CI] -40.1 to 47.6; P = 0.87). At 48 hours, we found no differences between the groups in pain severity (0.0, 95% CI -0.8 to 0.9; P = 0.94), pain interference (-0.3, 95% CI -1.4 to 0.8; P = 0.55), and morphine equivalent doses (6.5 mg, 95% CI -2.1 to 15.2; P = 0.14). Methylnaltrexone also did not affect the risk of severe disease (8%, 95% CI -11 to 28; P = 0.38) and mortality (6%, 95% CI -1 to 12; P = 0.11). The medication was well tolerated.
Discussion:
Methylnaltrexone treatment did not achieve superiority over placebo for reducing the severity of AP.
Insights
Methylnaltrexone did not improve acute pancreatitis (AP) severity in a clinical trial. This study found no significant difference between methylnaltrexone and placebo in managing AP symptoms or disease progression.
Area of Science:
- Gastroenterology
- Pharmacology
- Clinical Trials
Background:
- Opioids, used for severe pain in acute pancreatitis (AP), may worsen the condition via gastrointestinal and immune effects.
- Methylnaltrexone, a peripherally acting µ-opioid receptor antagonist, is investigated for its potential to counteract these opioid-induced effects without compromising pain relief.
Purpose of the Study:
- To evaluate the efficacy of methylnaltrexone in reducing the severity of acute pancreatitis.
- To assess the impact of methylnaltrexone on pain scores, opioid consumption, disease severity, and mortality in AP patients.
Main Methods:
- A double-blind, randomized, placebo-controlled trial was conducted with adult patients diagnosed with AP and systemic inflammatory response syndrome.
- Patients received either continuous intravenous methylnaltrexone or a placebo for 5 days, in addition to standard care.
- The primary endpoint was the Pancreatitis Activity Scoring System score at 48 hours; secondary outcomes included pain, opioid use, and mortality.
Main Results:
- The study randomized 105 patients to methylnaltrexone (n=51) or placebo (n=54).
- No significant difference was observed in the Pancreatitis Activity Scoring System scores between the methylnaltrexone and placebo groups at 48 hours (P=0.87).
- Methylnaltrexone did not significantly alter pain scores, opioid use, disease severity, or mortality rates compared to placebo.
Conclusions:
- Methylnaltrexone treatment did not demonstrate superiority over placebo in mitigating the severity of acute pancreatitis.
- The study concluded that methylnaltrexone is not effective in reducing AP severity under the tested conditions.
Related Concept Videos
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...